Broadwood Partners ups Insight Molecular (IMDX) stake in direct stock buy
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Insight Molecular Diagnostics Inc. reported that Broadwood Partners, L.P., a 10% owner, bought additional shares of its common stock. On February 10, 2026, Broadwood Partners agreed to acquire 521,739 common shares from the company in a registered direct offering for $2,999,999, or $5.75 per share, bringing its reported beneficial ownership to 11,931,839 shares.
The filing notes that these shares are directly owned by Broadwood Partners and may be deemed beneficially owned by Broadwood Capital, Inc. and Neal C. Bradsher, who each disclaim beneficial ownership beyond their economic interest. The group also reports warrants currently exercisable for 150,093 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 521,739 shares ($2,999,999)
Net Buy
5 txns
Insider
BROADWOOD PARTNERS, L.P., BROADWOOD CAPITAL INC, Bradsher Neal C
Role
10% Owner | 10% Owner | 10% Owner
Bought
521,739 shs ($3.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock, no par value | 521,739 | $5.75 | $3.00M |
| Purchase | Common Stock, no par value | 0 | $0.00 | -- |
| holding | Warrant to Purchase Common Stock | -- | -- | -- |
| holding | Warrant to Purchase Common Stock | -- | -- | -- |
| holding | Common Stock, no par value | -- | -- | -- |
Holdings After Transaction:
Common Stock, no par value — 11,931,839 shares (Direct);
Common Stock, no par value — 11,931,839 shares (Indirect, Footnote);
Warrant to Purchase Common Stock — 150,093 shares (Direct);
Warrant to Purchase Common Stock — 150,093 shares (Indirect, See Footnote)
Footnotes (1)
- The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. These securities are directly owned by Neal C. Bradsher. On February 10, 2026, Broadwood Partners entered into a Securities Purchase Agreement with Insight Molecular Diagnostics, Inc. (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 521,739 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a registered direct offering for a total purchase price of $2,999,999, or $5.75 per Common Share. These warrants are currently exercisable.
FAQ
What insider transaction did Broadwood Partners report for Insight Molecular Diagnostics (IMDX)?
Broadwood Partners reported buying 521,739 Insight Molecular Diagnostics common shares. The shares were purchased directly from the company in a registered direct offering, increasing the group’s reported beneficial ownership to 11,931,839 shares according to the Form 4 filing.